Effects of the Antimicrobial Peptide LL-37 and Innate Effector Mechanisms in Colistin-Resistant <i>Klebsiella pneumoniae</i> With <i>mgrB</i> Insertions.
Al-Farsi. Hissa M HM; Al-Adwani. Salma S; Ahmed. Sultan S; Vogt. Carmen C; Ambikan. Anoop T AT; Leber. Anna A; Al-Jardani. Amina A; Al-Azri. Saleh S; Al-Muharmi. Zakariya Z; Toprak. Muhammet S MS; Giske. Christian G CG; Bergman. Peter P
Key Findings
- Colistin‑resistant Klebsiella (due to mgrB insertions) are slightly more resistant to LL‑37, but only at concentrations of 50 µg/ml or higher.
- No change in bacterial surface charge or overall shape was seen between resistant and susceptible strains after LL‑37 exposure.
- Both resistant and susceptible strains survived equally well in human blood, serum, and a zebrafish infection model.
Practical Outcomes
- For DIY health enthusiasts, this means that using LL‑37 as an antimicrobial boost is unlikely to be compromised by colistin‑resistant bacteria under normal physiological conditions. High, non‑physiological doses might show some cross‑resistance, but such levels are not typical in the body. Overall, the findings suggest limited practical impact on everyday supplement or therapeutic use of LL‑37.
Summary
The study looked at whether bacteria that are resistant to the antibiotic colistin are also tougher against the natural human peptide LL‑37. They found that resistant Klebsiella strains do survive a bit better when LL‑37 is present at high doses, but at normal body‑level concentrations there’s no real difference, and the bacteria’s ability to cause infection stays the same.
Abstract
Colistin is a polypeptide antibiotic drug that targets lipopolysaccharides in the outer membrane of Gram-negative bacteria. Inactivation of the <i>mgrB</i>-gene is a common mechanism behind colistin-resistance in <i>Klebsiella pneumoniae</i> (Kpn). Since colistin is a cyclic polypeptide, it may exhibit cross-resistance with the antimicrobial peptide LL-37, and with other innate effector mechanisms, but previous results are inconclusive. To study potential cross-resistance between colistin and LL-37, as well as with other innate effector mechanisms, and to compare virulence of colistin-resistant and susceptible Kpn strains. Carbapenemase-producing Kpn from Oman (<i>n</i> = 17) were subjected to antimicrobial susceptibility testing and whole genome sequencing. Susceptibility to colistin and LL-37 was studied. The surface charge was determined by zeta-potential measurements and the morphology of treated bacteria was analyzed with electron microscopy. Bacterial survival was assessed in human whole blood and serum, as well as in a zebrafish infection-model. Genome-analysis revealed insertion-sequences in the <i>mgrB</i> gene, as a cause of colistin resistance in 8/17 isolates. Colistin-resistant (Col-R) isolates were found to be more resistant to LL-37 compared to colistin-susceptible (Col-S) isolates, but only at concentrations ≥50 μg/ml. There was no significant difference in surface charge between the isolates. The morphological changes were similar in both Col-R and Col-S isolates after exposure to LL-37. Finally, no survival difference between the Col-R and Col-S isolates was observed in whole blood or serum, or in zebrafish embryos. Cross-resistance between colistin and LL-37 was observed at elevated concentrations of LL-37. However, Col-R and Col-S isolates exhibited similar survival in serum and whole blood, and in a zebrafish infection-model, suggesting that cross-resistance most likely play a limited role during physiological conditions. However, it cannot be ruled out that the observed cross-resistance could be relevant in conditions where LL-37 levels reach high concentrations, such as during infection or inflammation.
Study Information
pubmed
2019
2019-11-14T00:00:00.000Z
10.3389/fmicb.2019.02632
19
53